Varma Mutual Pension Insurance Co Purchases 82,500 Shares of Pfizer Inc. $PFE

Varma Mutual Pension Insurance Co lifted its holdings in Pfizer Inc. (NYSE:PFE) by 9.4% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 960,563 shares of the biopharmaceutical company’s stock after acquiring an additional 82,500 shares during the quarter. Varma Mutual Pension Insurance Co’s holdings in Pfizer were worth $24,475,000 at the end of the most recent reporting period.

Several other institutional investors have also recently bought and sold shares of the business. Curio Wealth LLC increased its stake in shares of Pfizer by 36,600.0% in the second quarter. Curio Wealth LLC now owns 1,101 shares of the biopharmaceutical company’s stock valued at $27,000 after buying an additional 1,098 shares in the last quarter. Harbor Asset Planning Inc. acquired a new position in Pfizer during the 2nd quarter worth about $29,000. Grey Fox Wealth Advisors LLC bought a new stake in Pfizer during the 3rd quarter worth about $29,000. Howard Hughes Medical Institute acquired a new stake in Pfizer in the 2nd quarter valued at about $30,000. Finally, Darwin Wealth Management LLC bought a new position in shares of Pfizer in the second quarter worth about $32,000. Institutional investors own 68.36% of the company’s stock.

Trending Headlines about Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Q4 earnings beat and an upbeat outlook plus unusual call‑option activity suggest investors are bullish on near‑term upside. Pfizer Reports Strong Earnings Outlook
• Positive Sentiment: Post‑earnings bullish analysis argues the pullback could be a buying opportunity as fundamentals and buybacks support valuation. Pfizer: A Great Opportunity Post Earnings
• Positive Sentiment: Company returned $9.8B to shareholders in 2025 (buybacks/dividends), which supports per‑share metrics and investor demand. Pfizer Closes 2025 on Solid Note
• Positive Sentiment: Pfizer will collect $29M in an SEC‑related settlement, a small one‑time cash benefit and removal of legal overhang. Pfizer to collect $29 million
• Neutral Sentiment: Coverage pieces and screeners note Pfizer is trending and yields are attracting income investors; this supports interest but may cap upside if growth doubts persist. PFE Is a Trending Stock
• Neutral Sentiment: Analyses flag that pipeline progress and partnerships are real but must overcome a depressed valuation — potential upside if clinical wins arrive, but timing is uncertain. Pipeline Progress and Partnerships Tested
• Negative Sentiment: Daiwa downgraded PFE from outperform to neutral and set a $27 price target, signaling limited near‑term upside from their view. Daiwa Downgrade via Finviz
• Negative Sentiment: Commentary raises the risk Pfizer could be a value trap given fading COVID revenue and a looming 2026–2030 patent cliff; pipeline and M&A must offset lost blockbuster sales. Can New Drugs Offset Patent Cliff?
• Negative Sentiment: Opinion pieces question whether PFE is a value trap despite yields — these narratives can pressure sentiment if additional negative data or downgrades appear. Is Pfizer Stock Now A Value Trap?

Pfizer Stock Performance

PFE stock opened at $27.74 on Thursday. The business’s fifty day moving average is $25.74 and its 200-day moving average is $25.15. The company has a quick ratio of 0.97, a current ratio of 1.28 and a debt-to-equity ratio of 0.62. The company has a market cap of $157.70 billion, a P/E ratio of 20.39 and a beta of 0.47. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $27.94.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 EPS for the quarter, topping analysts’ consensus estimates of $0.57 by $0.09. The business had revenue of $17.56 billion during the quarter, compared to analysts’ expectations of $16.93 billion. Pfizer had a return on equity of 20.25% and a net margin of 12.42%.The firm’s quarterly revenue was down 1.2% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.63 earnings per share. Equities research analysts forecast that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, January 23rd will be paid a $0.43 dividend. The ex-dividend date of this dividend is Friday, January 23rd. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.2%. Pfizer’s dividend payout ratio is 126.47%.

Analyst Upgrades and Downgrades

Several analysts have recently commented on PFE shares. Guggenheim reissued a “buy” rating on shares of Pfizer in a research note on Wednesday, December 17th. Daiwa Securities Group downgraded Pfizer from an “outperform” rating to a “neutral” rating and set a $27.00 price objective on the stock. in a report on Thursday. Citigroup assumed coverage on Pfizer in a research report on Tuesday, December 2nd. They issued a “neutral” rating and a $26.00 price objective on the stock. Scotiabank initiated coverage on Pfizer in a research note on Thursday, November 13th. They issued a “sector outperform” rating and a $30.00 target price for the company. Finally, Weiss Ratings restated a “hold (c-)” rating on shares of Pfizer in a research report on Thursday, January 22nd. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, thirteen have issued a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, Pfizer presently has an average rating of “Hold” and an average target price of $28.00.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.